Role of insulin signaling in maintaining energy homeostasis

Endocrine Practice

Volumn 14, Issue 3, 2008, Pages 373-380

  Sharma, Morali D ^a   Garber, Alan J ^a   Farmer, John A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; DRUG DERIVATIVE;

ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; ENERGY BALANCE; ENERGY METABOLISM; FOOD INTAKE; GLUCONEOGENESIS; GLUCOSE TRANSPORT; HOMEOSTASIS; HUMAN; HUMAN TISSUE; HYPOGLYCEMIA; IN VIVO STUDY; METABOLIC DISORDER; MUSCLE TISSUE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; REVIEW; SIGNAL TRANSDUCTION; WEIGHT GAIN; ANIMAL; BRAIN; LIVER; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BRAIN; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; HOMEOSTASIS; HUMANS; INSULIN; LIVER; OBESITY; SIGNAL TRANSDUCTION;

EID: 48949090967     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.14.3.373     Document Type: Review

References (55)

1. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature. 2000;404:661-671.
2. Plum L, Belgardt BF, Brüning JC. Central insulin action in energy and glucose homeostasis. J Clin Invest. 2006; 116:1761-1766.
3. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001;414: 799-806.
4. White MF. Insulin signaling in health and disease. Science. 2003;302:1710-1711.
5. Kido Y, Nakae J, Accili D. Clinical review 125: the insulin receptor and its cellular targets. J Clin Endocrinol Metab. 2001;86:972-979.
6. Griffen SC, Russell SM, Katz LS, Nicoll CS. Insulin exerts metabolic and growth-promoting effects by a direct action on the liver in vivo: clarification of the functional significance of the portal vascular link between the beta cells of the pancreatic islets and the liver. Proc Natl Acad Sci U S A. 1987;84:7300-7304.
7. Girard J. The inhibitory effects of insulin on hepatic glucose production are both direct and indirect. Diabetes. 2006;55(Suppl 2):S65-S69.
8. Havel PJ. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol. 2002;13:51-59.
9. Gerozissis K. Brain insulin: regulation, mechanisms of action and functions [published correction appears in Cell Mol Neurobiol. 2003;23:873-874]. Cell Mol Neurobiol. 2003;23:1-25.
10. Gerozissis K. Brain insulin and feeding: a bi-directional communication. Eur J Pharmacol. 2004;490:59-70.
11. Plum L, Schubert M, Brüning JC. The role of insulin receptor signaling in the brain. Trends Endocrinol Metab. 2005;16:59-65.
12. Brennan AM, Mantzoros CS. Drug insight: the role of leptin in human physiology and pathophysiology-emerging clinical applications. Nat Clin Pract Endocrinol Metab. 2006;2:318-327.
13. Pocai A, Lam TK, Gutierrez-Juarez R, et al. Hypothalamic K(ATP) channels control hepatic glucose production. Nature. 2005;434:1026-1031.
14. Porte D Jr, Baskin DG, Schwartz MW. Leptin and insulin action in the central nervous system. Nutr Rev. 2002;60(10 part 2):S20-S29.
15. Schwartz MW, Porte D Jr. Diabetes, obesity, and the brain. Science. 2005;307:375-379.
16. Schwartz MW, Woods SC, Seeley RJ, Barsh GS, Baskin DG, Leibel RL. Is the energy homeostasis system inherently biased toward weight gain? Diabetes. 2003;52:232-238.
17. McGowan MK, Andrews KM, Kelly J, Grossman SP. Effects of chronic intrahypothalamic infusion of insulin on food intake and diurnal meal patterning in the rat. Behav Neurosci. 1990;104:373-385.
18. Hallschmid M, Benedict C, Schultes B, Fehm HL, Born J, Kern W. Intranasal insulin reduces body fat in men but not in women. Diabetes. 2004;53:3024-3029.
19. Brüning JC, Gautam D, Burks DJ, et al. Role of brain insulin receptor in control of body weight and reproduction. Science. 2000;289:2122-2125.
20. Tomaszuk A, Simpson C, Williams G. Neuropeptide Y, the hypothalamus and the regulation of energy homeostasis. Horm Res. 1996;46:53-58.
21. Williams G, Bing C, Cai XJ, Harrold JA, King PJ, Liu XH. The hypothalamus and the control of energy homeostasis: different circuits, different purposes. Physiol Behav. 2001;74:683-701.
22. Frankish HM, Dryden S, Hopkins D, Wang Q, Williams G. Neuropeptide Y, the hypothalamus, and diabetes: insights into the central control of metabolism. Peptides. 1995;16:757-771.
23. Wisse BE, Schwartz MW. Role of melanocortins in control of obesity. Lancet. 2001;358:857-859.
24. Porte D Jr. Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications. Diabetes Metab Res Rev. 2001;17:181-188.
25. Lazar MA. How obesity causes diabetes: not a tall tale. Science. 2005;307:373-375.
26. DCCT Research Group. Weight gain associated with intensive therapy in the Diabetes Control and Complications Trial. Diabetes Care. 1988;11:567-573.
27. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999;354:602]. Lancet. 1998;352:837-853.
28. Fritsche A, Häring H. At last, a weight neutral insulin? Int J Obes Relat Metab Disord. 2004;28(Suppl 2):S41-S46.
29. Jacob AN, Salinas K, Adams-Huet B, Raskin P. Weight gain in type 2 diabetes mellitus. Diabetes Obes Metab. 2007;9:386-393.
30. Sallé A, Ryan M, Guilloteau G, Bouhanick B, Berrut G, Ritz P. "Glucose control-related" and "non-glucose control-related" effects of insulin on weight gain in newly insulin-treated type 2 diabetic patients. Br J Nutr. 2005;94: 931-937.
31. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13(Suppl 1):1-68.
32. Peterson GE. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir. Curr Med Res Opin. 2006;22:2613-2619.
33. Haak T, Tiengo A, Draeger E, Suntum M, Waldhäusl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2005;7:56-64.
34. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia. 2004;47: 622-629.
35. Home P, Bartley P, Russell-Jones D, et al (Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability [STEADINESS] Study Group). Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care. 2004;27:1081-1087.
36. Pieber TR, Draeger E, Kristensen A, Grill V. Comparison of three multiple injection regimens for type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med. 2005;22:850-857.
37. Raslová K, Bogoev M, Raz I, Leth G, Gall MA, Hâncu N. Insulin detemir and insulin aspart: a promising basalbolus regimen for type 2 diabetes [published correction appears in Diabetes Res Clin Pract. 2006;72:112]. Diabetes Res Clin Pract. 2004;66:193-201.
38. Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther. 2004;26:724-736.
39. Hermansen K, Davies M, Derezinski T, Ravn GM, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes [published correction appears in Diabetes Care. 2007;30:1035]. Diabetes Care. 2006;29:1269-1274.
40. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Comparison of oncedaily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes [published correction appears in Clin Ther. 2006;28:1967]. Clin Ther. 2006;28:1569-1581.
41. Rosenstock J, Davies M, Home PD, Larsen J, Tamer SC, Schernthanr G. Insulin detemir added to oral antidiabetic drugs in type 2 diabetes provides glycemic control comparable to insulin glargine with less weight gain [abstract]. Diabetes. 2006;55(Suppl 1):A132.
42. Garber AJ, Kim H, Draeger E. Treatment with insulin detemir provides improved glycaemic control and less weight gain compared to NPH insulin in people with diabetes [abstract 150]. Diabetologia. 2004;47(Suppl 1):A58.
43. Fulcher GR, Gilbert RE, Yue DK. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Intern Med J. 2005;35:536-542.
44. Raskin P, Klaff L, Bergenstal R, Hallé JP, Donley D, Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care. 2000;23:1666-1671.
45. Fritsche A, Schweitzer MA, Häring HU (4001 Study Group). Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2003;138: 952-959.
46. Massi Benedetti M, Humburg E, Dressler A, Ziemen M. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res. 2003;35:189-196.
47. Riddle MC, Rosenstock J, Gerich J (Insulin Glargine 4002 Study Investigators). The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080-3086.
48. Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006; 49:442-451.
49. Kølendorf K, Ross GP, Pavlic-Renart I, et al. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in type 1 diabetes. Diabet Med. 2006;23:729-735.
50. Pieber TR, Treichel HC, Hompesch B, et al. Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy. Diabet Med. 2007;24:635-642.
51. Davies M, Derezinski T, Kim H, Clauson P. No correlation between weight gain and number of hypoglycemic events in patients with type 2 diabetes treated with insulin detemir as compared to NPH insulin [abstract]. Diabetes. 2006;55(Suppl 1):A466.
52. Havelund S, Plum A, Ribel U, et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res. 2004;21:1498-1504.
53. Hordern SV, Wright JE, Umpleby AM, Shojaee-Moradie F, Amiss J, Russell-Jones DL. Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp. Diabetologia. 2005;48:420-426.
54. Hennige AM, Sartorius T, Tschritter O, et al. Tissue selectivity of insulin detemir action in vivo. Diabetologia. 2006;49:1274-1282.
55. Tschritter O, Porubska K, Hennige AM, et al. Neuronal activation of the human cerebral cortex by administration of insulin detemir compared to human insulin [abstract]. Diabetologia. 2005;48(Suppl 1):A256.